Insulin Producing Stem Cell Transplantation Clinical Trial in Type 1 Diabetes

Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age15-18
SponsorAin Shams University

About this trial

Type 1 Diabetes is a chronic autoimmune disease. It results from autoimmune destruction of pancreatic Beta cells leading to absolute insulin insufficiency. The establishment of pluripotent like human stem cells derived from adipose tissue derived mesenchymal cell origin have introduced a new potential source for cell therapy in type 1 diabetic patients, especially in light of recent successes in producing glucose-sensitive insulin secreting cells and this will be the scope of this study. In the last decade, human clinical trials of introducing insulin producing stem cells from various origins were approved and conducted.

Eligibility criteria

Qualifiers

Type 1 diabetes

Disqualifiers

patients with other autoimmune diseases

patients with micro or macro vascular complications

patients with other chronic diseases

Trial design

Treatments tested in this trial

  • Insulin producing stem cells infusion

Treatment groups

20 Participants
are divided into 2 treatment groups

Sponsors and collaborators